Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-02-23
2008-09-02
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S143100, C530S387100, C530S388220
Reexamination Certificate
active
07419666
ABSTRACT:
The invention includes a method of treating an intraocular disorder in a mammal, the method comprising administering to the mammal a Very Late Antigen-4 (VLA-4) antagonist for the treatment of selected ocular disorders.
REFERENCES:
patent: 5871734 (1999-02-01), Lobb et al.
patent: 5888507 (1999-03-01), Burkly
patent: 5932214 (1999-08-01), Lobb et al.
patent: 6291511 (2001-09-01), Durette et al.
patent: 6465513 (2002-10-01), Grant et al.
patent: 6479492 (2002-11-01), Konradi et al.
patent: 6492372 (2002-12-01), Konradi et al.
patent: 6495525 (2002-12-01), Lee et al.
patent: 6524581 (2003-02-01), Adamis
patent: 6545003 (2003-04-01), Grant et al.
patent: 6559127 (2003-05-01), Dappen et al.
patent: 6583139 (2003-06-01), Thorsett et al.
patent: 6586602 (2003-07-01), Thorsett et al.
patent: 6602503 (2003-08-01), Lobb et al.
patent: 6608101 (2003-08-01), Ni et al.
patent: 6630512 (2003-10-01), Adams et al.
patent: 6685617 (2004-02-01), Blinn et al.
patent: 6686350 (2004-02-01), Zheng et al.
patent: 6852878 (2005-02-01), Meng et al.
patent: 6903088 (2005-06-01), Konradi et al.
patent: 7026501 (2006-04-01), Kawaguchi et al.
patent: 7157086 (2007-01-01), Lobb et al.
Martin et al. (2005). Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 46(6):2056-2063.
Hafezi-Moghadam et al. (2007). VLA-4 blockade suppresses endotoxin-induced uveitis: in vivo evidence for functional integrin up-regulation. FASEB J. 21(2):464-474.
Albertini et al. (1998) “Elevated Concentrations of Soluble E-Selectin and Vascular Cell Adhesion Molecule-1 in NIDDM: Effects of intensive insulin treatment,” Diabetes Care 21(6): 1008-13.
Bai et al. (2003) “Increased expression of intercellular adhesion molecule-1, vascular cellular adhesion molecule-1 and leukocyte common antigen in diabetic rat retina,” Yan Ke Xue Bao 19(3): 176-83.
Barile et al. (1999) “Soluble cellular adhesion molecules in proliferative vitreoretinopathy and poliferative diabetic retinopathy,” Curr. Eye Res. 19(3): 219-27.
Barouch et al. (2000) “Integrin-Mediated Neutrophil Adhesion and Retinal Leukostasis in Diabetes,” Invest. Ophthalmol. Vis. Sci. 41: 1153-58.
Beck et al. (1993) “Optic Neuritis Treatment Trial,” Arch. Ophthalmol. 111: 773-775.
Berson et al. (1993) “A Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa,” Arch. Ophthalmol. 111: 761-772.
Boerner et al. (1991) “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes,” J. Immunol. 147: 86-95.
Brinchmann-Hansen et al. (1992) “Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study,” BMJ 304(6818): 19-22.
Devine et al. (1996) “Role of LFA-1, ICAM-1, VLA-4 and VCAM-1 in lymphocyte migration across retinal pigment epithelial monolayers in vitro,” Immunology 88(3): 456-62.
DRS Coordinating Center, Dept. of Epidemiol. and Prevent Medicine (1981) “Photocoagulation Treatment of Proliferative Diabetic Retinopathy: Relationship of Adverse Treatment Effects to Retinopathy Severity: Diabetic Retinopathy Study Report No. 5,” Dev. Ophthal. 2: 248-261.
DRS Research Group (1981) “Photocoagulation Treatment of Proliferative Diabetic Retinopathy: Clinical Application of Diabetic Retinopathy Study (DRS) Findings, DRS Report No. 8,” Ophthalmol. 88(7): 583-600.
Fasching et al. (1996) “Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus,” J. Clin. Endocrinol. Metab. 81(12): 4313-17.
Fryer et al. (1997) “Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptors in antigen-challenged guinea pig airways,” J. Clin. Invest. 99: 2036-44.
Ghosh et al. (2003) “Natalizumab for Active Crohn's Disease,” N. Eng. J. Med. 348(1): 24-32.
Hernandez (2001) “Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study,” Diatetes Care 24(3): 516-21.
Hynes et al. (2002) “Integrins: bidirectional, allosteric signalling machines,” Cell 110: 673-687.
Kado et al. (1999) “Circulating intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin in patients with type 2 diabetes mellitus,” Diabetes Res. Clin. Pract. 46(2): 143-48.
Karma et al. (1988) “Course and Outcome of Ocular Sarcoidosis,” Amer. J. Ophthalmol. 106: 467-472.
Kim et al. (2001) “Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells,” J. Biol. Chem. 276(10): 7614-7620.
Kumar et al. (2001) “Targeting of vasculature in cancer and other angiogenic diseases,” Trends Immunol. 22(3): 129.
Kuppner et al. (1993) “Adhesion molecule expression in acute and fibrotic sympathetic ophthalmia,” Curr. Eye Res. 12(10): 923-934.
La Heij et al. (1998) “Adhesion molecules in iris biopsy specimens from patients with uveitis,” Br. J. Ophthalmol. 82: 432-437.
Limb et al. (1996) “Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy,” Br. J. Ophthalmol. 80(2): 168-73.
Limb et al. (1999) “Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy,” Invest Ophthalmol. Vis. Sci. 40(10): 2453-57.
Lutty et al. (1997) “Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid,” Am. J. Pathol. 151(3) 707-714.
Macular Photocoagulation Study Group (1982) “Argon Laser Photocoagulation for Senile Macular Degeneration: Results of a Randomized Clinical Trial,” Arch. Ophthalmol. 100: 912-918.
Martin et al. (2005) “Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis,” Invest Ophthalmol. Vis. Sci. 46(6): 2056-63.
Matsumoto et al. (2002) “Comparison of serum concentrations o fsoluble adhesion molecules in diabetic microangiopathy and macroangiopathy,” Diabet. Med. 19(10) 822-826.
McLeod et al. (1995) “Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid,” Am. J. Pathol. 147(3): 642-653.
Melder et al. (1996) “During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor andothelium,” Nat. Med. 2(9) 992-997.
Miller et al. (2003) “A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis,” N. Eng. J. Med. 348(1): 15-22.
Miyamoto et al. (1998) “In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats,” Invest Ophthalmol. Vis. Sci. 39(11): 2190-94.
Miyamoto et al. (1999) “Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition,” PNAS USA 96(19) 10836-41.
Olson et al. (1997) “Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration,” Diabetologia 40(10): 1166-71.
Penfold et al. (1984) “An ultrastructural study of the role of leucocytes and fibroblasts I nthe breakdown of Bruch's membrane,” Austral. J. Ophthamol. 12: 23-31.
Penfold et al. (1985) “Senile Macular Degeneration: The involvement of immunocompetent cells,” Graefe's Arch. Clin. Exp. Ophthalmol. 223: 69-76.
Penfold et al. (1987) “Age-related macular degeneration: ultrastructural studies of the relationship of leucocytes to angiogen
Adamis Anthony P.
Gragoudas Evangelos S.
Iliaki Eirini
Miller Joan W.
Goodwin & Procter LLP
Lockard Jon M
Massachusetts Eye and Ear Infirmary
Saoud Christine J
LandOfFree
Treatment of ocular disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of ocular disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of ocular disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988919